Identification of a new G-protein-linked receptor for growth hormone secretagogues.

Pong SS, Chaung LY, Dean DC, Nargund RP, Patchett AA, Smith RG

Molecular endocrinology (Baltimore, Md.)1 Jan 1996Cited by 128 (Europe PMC)

PMID8838145DOI10.1210/mend.10.1.8838145PepBankPUB-08838145

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone15

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In porcine and rat pituitary membranes, a high-affinity binding site mediated activity of secretagogues including MK-0677.
In plain wordsIn lab tests, secretagogues including MK-0677 acted through a high-affinity binding site in pig and rat pituitary membranes.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableHigh-affinity binding site
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814509
02LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In pituitary membrane studies, binding affinity of pooled secretagogues including MK-0677 correlated tightly with GH-secretory activity.
In plain wordsIn lab tests, stronger binding by secretagogues including MK-0677 correlated with stronger growth hormone release.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableBinding affinity and GH-secretory activity correlation
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The binding affinity of these structurally diverse secretagogues is tightly correlated with GH-secretory activity.
2 context sentences(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
Summary · context
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814510
03LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In pituitary membranes, binding of pooled secretagogues including MK-0677 depended on magnesium.
In plain wordsIn lab tests, binding of secretagogues including MK-0677 depended on magnesium.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableMagnesium-dependent binding
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin.
2 context sentences(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
Summary · context
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814511
04LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In pituitary membranes, GTP-gamma-S inhibited binding of pooled secretagogues including MK-0677.
In plain wordsIn lab tests, GTP-gamma-S reduced binding of secretagogues including MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseBinding inhibition by GTP-gamma-S
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin.
2 context sentences(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
Summary · context
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814512
05LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In pituitary membranes, GHRH did not displace binding of pooled secretagogues including MK-0677.
In plain wordsIn lab tests, GHRH did not displace binding of secretagogues including MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeBinding displacement by GHRH
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin.
2 context sentences(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
Summary · context
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814513
06LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In pituitary membranes, somatostatin did not displace binding of pooled secretagogues including MK-0677.
In plain wordsIn lab tests, somatostatin did not displace binding of secretagogues including MK-0677.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeBinding displacement by somatostatin
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin.
2 context sentences(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
Summary · context
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814514
07LabNot a test of MK-677 (ibutamoren) aloneEx vivo tissueMechanism
In pituitary membrane studies, the receptor for secretagogues including MK-0677 differed from the GHRH receptor and had G-protein-coupled receptor properties.
In plain wordsIn lab tests, the receptor for secretagogues including MK-0677 differed from the GHRH receptor and showed G-protein-coupled properties.
Peptide
MK-677 (ibutamoren)
Outcome
Not applicableG-protein-coupled receptor properties
Study
porcine and ratn: not reported in source
anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Pharmacology
Source sentences
Summary
The receptor is distinct from that for GHRH and has the properties of a new G-protein-coupled receptor.
2 context sentences(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
Summary · context
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).
Report a problemFND-0883814515
08LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism
A specific high-affinity binding site that mediates the activity of GH secretagogues, including GHRP‑6, was identified in porcine and rat anterior pituitary membranes.
In plain wordsIn lab tests, pig and rat pituitary membranes had a binding site for a group of GH-releasing compounds that includes GHRP‑6.
Peptide
GHRP-6
Outcome
Not applicableBinding site for GH secretagogues
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0883814501
09LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism
A specific high-affinity binding site that mediates the activity of GH secretagogues, including hexarelin, was identified in porcine and rat anterior pituitary membranes.
In plain wordsIn lab tests, pig and rat pituitary membranes had a binding site for a group of GH-releasing compounds that includes hexarelin.
Peptide
Hexarelin
Outcome
Not applicableBinding site for GH secretagogues
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
A specific high affinity binding site in porcine and rat anterior pituitary membranes that mediates the activity of these secretagogues has now been identified.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0883814502
10LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism
The binding affinity of the structurally diverse secretagogues, including GHRP‑6, was tightly correlated with GH-secretory activity.
In plain wordsIn lab tests, how tightly a group of GH-releasing compounds that includes GHRP‑6 bound matched how strongly they released growth hormone.
Peptide
GHRP-6
Outcome
Not applicableBinding affinity versus GH-secretory activity
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The binding affinity of these structurally diverse secretagogues is tightly correlated with GH-secretory activity.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0883814503
11LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism
The binding affinity of the structurally diverse secretagogues, including hexarelin, was tightly correlated with GH-secretory activity.
In plain wordsIn lab tests, how tightly a group of GH-releasing compounds that includes hexarelin bound matched how strongly they released growth hormone.
Peptide
Hexarelin
Outcome
Not applicableBinding affinity versus GH-secretory activity
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The binding affinity of these structurally diverse secretagogues is tightly correlated with GH-secretory activity.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0883814504
12LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism
Secretagogue binding was Mg(2+)-dependent, inhibited by GTP-gamma-S and not displaced by GHRH or somatostatin.
In plain wordsIn lab tests, binding of the GH-releasing compounds, GHRP‑6 among them, needed magnesium and was not displaced by GHRH or somatostatin.
Peptide
GHRP-6
Outcome
Not applicableProperties of secretagogue binding
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0883814505
13LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism
Secretagogue binding was Mg(2+)-dependent, inhibited by GTP-gamma-S and not displaced by GHRH or somatostatin.
In plain wordsIn lab tests, binding of the GH-releasing compounds, hexarelin among them, needed magnesium and was not displaced by GHRH or somatostatin.
Peptide
Hexarelin
Outcome
Not applicableProperties of secretagogue binding
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The binding is Mg(2+)-dependent, is inhibited by GTP-gamma-S, and is not displaced by GHRH and somatostatin.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0883814506
14LabNot a test of GHRP-6 aloneIn vitro (cell-free)Mechanism
The secretagogue receptor is distinct from the GHRH receptor and has the properties of a new G-protein-coupled receptor.
In plain wordsIn lab tests, the receptor for these GH-releasing compounds, GHRP‑6 among them, differs from the GHRH receptor and looks like a G-protein-coupled receptor.
Peptide
GHRP-6
Outcome
Not applicableIdentity of the secretagogue receptor
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The receptor is distinct from that for GHRH and has the properties of a new G-protein-coupled receptor.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0883814507
15LabNot a test of Hexarelin aloneIn vitro (cell-free)Mechanism
The secretagogue receptor is distinct from the GHRH receptor and has the properties of a new G-protein-coupled receptor.
In plain wordsIn lab tests, the receptor for these GH-releasing compounds, hexarelin among them, differs from the GHRH receptor and looks like a G-protein-coupled receptor.
Peptide
Hexarelin
Outcome
Not applicableIdentity of the secretagogue receptor
Study
pig, ratn: not reported in source
Anterior pituitary membranes
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
The receptor is distinct from that for GHRH and has the properties of a new G-protein-coupled receptor.
1 context sentence(design, population, supporting numbers)
Summary · context
The spiroindoline MK-0677, the benzolactam L-692,429, and the peptides, GHRP-6 and hexarelin, have been shown to possess potent and selective GH-secretory activity in several species including human.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-0883814508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
14 Oct 2026, 01:46 UTC
Study data updated · source update from Europe PMC
Version 3
13 Oct 2026, 21:44 UTC
Study results updated
Version 2
13 Oct 2026, 16:31 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.